Steen S, Karlsson E, Bjornheden I, Rask G, et al. Pathological response to pembrolizumab-based neoadjuvant therapy in ER-low vs. ER-zero breast cancer: a Swedish population-based cohort study. Breast Cancer Res 2025;27:213.
PMID: 41316480